Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinic Patient…
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinic Patient…
RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous…
How can aging be delayed? Graz-based heart scientist Mahmoud Abdellatif, MD PhD (Doctor of Medicine and Philosophy) has…
The University Hospital Aalborg (Denmark) yesterday has imaged the first patient with Eckert and Ziegler’s Gallium (68Ga…
. Europäisches Patentamt (EPA) zeichnet Robert Grass und Wendelin Stark (CH) für Speichermethode aus, die digitale Dat…
Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA2…
Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and develop…
IMA203CD8 is a 2nd-generation product candidate co-expressing Immatics’ proprietary CD8αβ co-receptor engaging funct…
Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses in…
Over the century, the technique of manufacturing of clay brick has not experienced much change across the world. These a…